Trial Profile
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; Inbakicept (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Lymphoma; Myelodysplastic syndromes; Myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
- 28 Jul 2020 Status changed from active, no longer recruiting to completed.
- 11 Nov 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Feb 2020.
- 27 Aug 2019 Planned End Date changed from 1 Jun 2020 to 1 Oct 2019.